Psychedelic Use Shows Highly Variable Effects in Psychosis
Variability in outcomes and subjective effects of psychedelic use in psychotic populations: Case-based evidence from naturalistic settings https://t.co/DtHP4jbmM8
Trans Voices Show Psychedelics Unlock Authentic Self
Altered states, authentic selves: Trans individual’s experiences with psychedelics and their implications for Psychedelic-Assisted Psychotherapy https://t.co/aDdpDYwDy8
Classic Psychedelics Offer New Hope for Chronic Pain
Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians https://t.co/Vmm81ZVO8F
Iboga Microdosing Shows Clinical Gains in Brain Injury
Clinical Improvement Following an Integrative Iboga Microdosing Protocol in Post-Concussive and Hypoxic Brain Injury Syndromes: A Case Series https://t.co/VVlzsjyxRT
Neuroscientist Exposes Psychedelic Hype Behind Biotech Boom
Neuroscientist Gül Dölen, live and unfiltered — on psychedelics, plasticity, and the beautiful lie at the heart of the biotech boom. https://t.co/QEIrhJ2Ik3
New Patent Covers Short-Acting Monoamine Releasers
Short-acting monoamine releasers D Nutt, A Borthwick, R Tyacke - US Patent 12,590,077, 2026 https://t.co/P99hvyXiil
5-HT1A Blockade Amplifies DMT’s Subjective Experience
5-HT1A receptor blockade potentiates the subjective effects of DMT Zarmeen Zahid, Rick J. Strassman, Clifford R. Qualls, Sandeep M. Nayak, 2026 https://t.co/5tCpjw2Iaz
R‑MDDMA Boosts Neuroplasticity and Ant
methylated MDMA analog in animals R-MDDMA "still promoted structural neuroplasticity in cortical neurons, facilitated fear extinction learning, and produced sustained antidepressant-like effects" did not directly activate 5-HT2B receptors https://t.co/w0ltV7VXQL
2C‑B Shows Dose‑Dependent Effects Similar to MDMA and Psilocybin
Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants https://t.co/OEJPk0XTqg
Global Psychedelic Survey Shows Health Gains and Transformations
Field Notes From Inner Space: Global Psychedelic Survey Participants Report Health Benefits, Personal Growth, and Life Transformations https://t.co/EuRatxBQf1
We Covered Psychedelics for Brain Injury Back in 2021
psychedelics for brain injury trending now, you say? yes, we wrote about it in 2021. full article below. https://t.co/RcXtd2XIe0
Psychedelics May Reverse Epigenetic Roots of Addiction
Epigenetic Mechanisms of Psychedelics in Addiction: Emerging Evidence and Therapeutic Potential these compounds may directly counteract the epigenetic and transcriptional imprints that sustain compulsive substance use https://t.co/GJyHoLPL83
New Psychedelic Trials Target Depression and PTSD
Compass Pathways’ psilocybin (COMP360) for treatment-resistant depression (TRD) Usona Institute’s psilocybin for major depressive disorder (MDD) Otsuka’s methylone (TSND-201) for PTSD
Psilocybin Reconfigures Cortical Inhibition via Interneuron Recruitment
wonky / important pre-clinial paper out of Alex Kwan's lab Psilocybin reshapes cortical inhibition through selective interneuron recruitment @kwanalexc https://t.co/OZX2cHDD94
Social Support Beats Policy‑blind Trauma Treatment for Recovery
Treating trauma while ignoring the social and political conditions that generate it risks turning medicine into a repair shop for problems our policies continue to produce. The strongest predictor of sustained recovery from addiction is social support. https://t.co/HoXy8efgWf